EU5 Physician and Payer Perspectives on Improved Renal Therapies Versus Tightening Healthcare Budgets | Physician & Payer Forum | EU5 | 2015

A Survey of Nephrologists and Interviews with Payers in the EU5

Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs)/oral/IV iron and phosphate binders, respectively. The market for renal therapies is poised to expand owing to the growing size of the CKD patient population, as well as the expected launches of novel therapies such as oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors to treat renal anemia (i.e., roxadustat, AKB-6548, GSK-1278863A), an IV iron that could reduce the need for ESAs (i.e., Triferic), an IV calcimimetic (i.e., AMG-416), and iron-based phosphate binders to treat hyperphosphatemia and potentially iron deficiency anemia as well (i.e., Auryxia).

Login to access report